

Supplemental Tables for:
Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as initial therapy in HR+, HER2-advanced breast cancer
Gregory L. Price et al.

Supplemental Table 1. Detailed information on specific items of the EORTC QLQ-C30 and EORTC BR23.

Functional or symptom scale	Specific items asked about ¹
EORTC QLQ-C30²⁰	
Global health status²	Rating of overall health
	Rating of overall quality of life
Functioning	
Cognitive ²	Difficulty concentrating (i.e. reading, television show)
	Difficulty with memory
Emotional ²	Feeling tense
	Worrying
	Irritability
	Feeling depressed
Physical ²	Difficulty completing strenuous activities (i.e. carrying a heavy bag)
	Difficulty taking a long and/or a short walk.
	Remaining in bed or in a chair all day.
	Difficulty eating, dressing, washing, or toileting independently

Role ²	Difficulty in completing work or daily activities
	Limited in participating in hobbies or other leisure time activities
Social ²	Physical or medical condition interfering with family life
	Physical or medical condition interfering with social activities
Symptoms	
Appetite loss ²	Lacking appetite
Constipation ²	Experienced constipation
Diarrhea ²	Experienced diarrhea
Dyspnea ²	Shortness of breath
Fatigue ²	Requiring rest
	Felt weak
	Felt tired
Financial difficulties ²	Physical condition or medical treatment contributing to financial difficulties
Insomnia ²	Difficulty sleeping
Nausea/vomiting ²	Felt nauseous
	Vomited
Pain ²	Experienced pain
	Pain interfering with daily activities

EORTC BR23²¹	
Functioning	
Body image ²	Feeling physically less attractive as a result of disease or treatment
	Feeling less feminine as a result of disease or treatment
	Difficulty looking at body naked
	Feeling dissatisfied with body
Sexual functioning ³	Interest in sex
	Amount of sexual activity
Sexual enjoyment ³	If sexually active, ability to enjoy sex
Future perspective ²	Experiencing worry about future health
Symptoms	
Systemic therapy side effects ²	Dry mouth
	Hair loss
	Feeling ill or well
	Experiencing hot flushes
	Experiencing headaches
Breast symptoms ²	Experiencing pain in affected breast
	Swelling in affected breast
	Sensitivity in affected breast

	Skin problems in the affected breast (i.e. itchy, flaky, dry)
Arm symptoms ²	Pain in arm or shoulder
	Swelling in arm or hand
	Difficulty raising arm or moving arm side to side
Upset by hair loss ²	If patient has experienced hair loss, is that upsetting?

¹Please note this is not the specific wording of items, but summarizes what activities, behaviors and symptoms are asked about.

²Time frame for these items was past week.

³Time frame for these items was past 4 weeks.

Abbreviations: EORTC QLQ-BR23, European Organization for Research and Treatment of Cancer Breast Cancer-Specific Quality-of-Life Questionnaire; EORTC QLQ-C30, European Organization for the Research and Treatment of Cancer, Quality-of-Life Questionnaire Core 30.

Supplemental Table 2. Patient compliance (%) for the EORTC QLQ-C30 and BR23 by study arm and visit.

Planned visit	Main reason if not compliant	Abemaciclib + NSAID n=327	Placebo + NSAID n=161	Abemaciclib + NSAID n=327	Placebo + NSAID n=161
		QLQ-C30		BR23	
Baseline		96.9	98.1	95.7	97.5
	Missing	3.1	1.9	4.3	2.5
	Other	0	0	0	0
	Study site failed to administer	0	0	0	0
	Subject refusal	0	0	0	0
Cycle 3		98.3	98.6	97.3	98.6
	Missing	0	0	0	0
	Other	1.0	0.7	1.7	1.4
	Study site failed to administer	0.3	0	0.3	0
	Subject refusal	0.3	0.7	0.7	0
Cycle 5		97.0	97.6	96.6	96.9
	Missing	0	0.8	0	0.8
	Other	0.8	0.8	1.1	0.8
	Study site failed to administer	1.5	0.8	1.5	0.8

	Subject refusal	0.8	0	0.8	0.8
Cycle 7		97.2	95.7	97.2	96.6
	Missing	0	0	0	0
	Other	0.8	0.9	0.8	1.7
	Study site failed to administer	0.8	3.4	1.2	0.9
	Subject refusal	1.2	0	0.8	0.9
Cycle 9		96.9	97.2	96.5	96.3
	Missing	0	0	0	0
	Other	1.3	0	1.3	0.9
	Study site failed to administer	1.3	1.9	1.7	1.9
	Subject refusal	0.4	0.9	0.4	0.9
Cycle 11		94.5	96.9	94.5	95.9
	Missing	0	0	0	0
	Other	0.9	0	0.5	1.0
	Study site failed to administer	3.2	1.0	3.7	1.0
	Subject refusal	1.4	2.0	1.4	2.0
Cycle 13		94.1	95.4	95.1	95.4
	Missing	0	0	0	0

	Other	1.5	1.1	1.0	1.1
	Study site failed to administer	3.0	1.1	2.5	1.1
	Subject refusal	1.5	1.1	1.5	2.3
Cycle 15		95.7	96.4	95.1	96.4
	Missing	0	0	0	0
	Other	2.7	1.2	2.7	1.2
	Study site failed to administer	1.1	1.2	1.6	1.2
	Subject refusal	0.5	1.2	0.5	1.2
Cycle 17		96.6	95.9	96.0	94.5
	Missing	0	0	0	0
	Other	1.1	2.7	1.1	4.1
	Study site failed to administer	1.1	0	1.7	0
	Subject refusal	1.1	1.4	1.1	1.4
Cycle 19		96.4	90.8	95.8	92.3
	Missing	0	0	0	0
	Other	1.2	4.6	1.3	3.1
	Study site failed to administer	1.8	3.1	0.6	1.5
	Subject refusal	0.6	1.5	0.6	0

Cycle 22		88.0	81.0	88.0	81.0
	Missing	0.7	0	0.7	0
	Other	4.0	5.2	4.0	5.2
	Study site failed to administer	4.7	10.3	4.7	10.3
	Subject refusal	2.7	3.4	2.7	3.4
Cycle 25		94.9	92.2	94.1	94.1
	Missing	0	0	0	0
	Other	2.9	0	2.9	0
	Study site failed to administer	2.2	5.9	2.2	5.9
	Subject refusal	0	2.0	0.7	0
Post-discontinuation Follow-up		71.6	70.8	71.6	69.0
	Missing	0	0	0	0
	Other	8.5	10.6	8.5	12.4
	Study site failed to administer	4.5	6.2	4.5	7.1
	Subject refusal	15.3	12.4	15.3	11.5

Abbreviations: EORTC QLQ-BR23, European Organization for Research and Treatment of Cancer Breast Cancer-Specific Quality-of-Life Questionnaire; EORTC QLQ-C30, European Organization for the Research and Treatment of Cancer, Quality-of-Life Questionnaire Core 30; mBPI-sf, Modified Brief Pain Inventory—short form; n, number of patients.

*For 1 person, the reason for not completing the BR23 was known to be translation not available, which is categorized as other in this table.